FDA approves darolutamide for treatment of nmCRPC

Posted on July 31, 2019 by Sitemaster

Bayer’s US pharmaceutical division has announced that the US Food and Drug Administration (FDA) has approved darolutamide — their formerly investigational androgen receptor inhibitor — for the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 3 Comments »

Darolutamide (ODM-201) in the treatment of nmCRPC

Posted on March 28, 2019 by Sitemaster

Earlier this year we had reported on the initial presentation of data demonstrating the efficacy and safety of darolutamide (formerly known as ODM-201), a third “super-antiandrogen” — similar to enzalutamide (Xtandi) and apalutamide (Erleada), in the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Uncategorized | Tagged: , , , , , | Leave a comment »

Darolutamide (ODM-201) in the treatment of nmCRPC

Posted on February 15, 2019 by Sitemaster

Also on Thursday in San Francisco, Dr. Karim Fizazi presented the initial results from the ARAMIS trial of darolutamide (formerly known as ODM-201) in the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Uncategorized | Tagged: , , , , , | 6 Comments »

Apalutamide (Erleada) approved in EU for treatment of nmCRPC

Posted on January 17, 2019 by Sitemaster

Yesterday, Janssen Pharmaceuticals announced the approval of apalutamide (Erleada) by the European Commission (EC) for the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC) who are at high risk for development of metastatic disease. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | 2 Comments »

Evolution in the management of nmCRPC

Posted on August 21, 2018 by Sitemaster

With the relatively recent approvals of apalutamide (Erleada) and enzalutamide (Xtandi) for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC), we are seeing intense discussion within the urologic oncology and medical oncology communities about the appropriate treatment of patients with this category of prostate cancer. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 3 Comments »

FDA approves use of enzalutamide (Xtandi) for nmCRPC

Posted on July 16, 2018 by Sitemaster

As we predicted just a couple of weeks ago, on Friday the US Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC), … READ MORE …

Filed under: Living with Prostate Cancer, Management | Tagged: , , , , | Leave a comment »

Evolutions in the treatment of nmCRPC — redux

Posted on February 9, 2018 by Sitemaster

So at the Genitourinary Cancers Symposium in San Francisco today we were presented with full reports on the SPARTAN trial and the PROSPER trial by Drs. Eric Small and Maha Hussain, respectively. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 6 Comments »

Next Page »